Corvus Pharmaceuticals, Inc.CRVSNASDAQ
Loading
Other Income/Expenses (Net) Over TimeExpanding
Percentile Rank91
5Y CAGR-6.0%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

5Y CAGR
-6.0%/yr
Long-term compound
Percentile
P91
Near historical high
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$27.69M+179.7%
2024$-34.74M-859.3%
2023$-3.62M+58.6%
2022$-8.74M-89.6%
2021$-4.61M-112.2%
2020$37.77M+1630.8%
2019$2.18M-4.4%
2018$2.28M+165.2%
2017$861000.00+43.3%
2016$601000.00-